Artrya Limited CEO & Co-Founder John Konstantopoulos talked with Jonathan Jackson from Proactive at the Small and Mid-Cap Conference about the company’s AI-driven approach to transforming heart disease detection and diagnosis. He explained that heart disease remains the leading cause of death globally, often going undetected until it is too late. Konstantopoulos highlighted a key issue in current diagnostics, stating, “what is really causing the heart attack is a soft inflammation that forms early on and doctors don’t see it.” Artrya’s solution uses artificial intelligence to analyse coronary angiograms and identify inflammatory plaque in real time, enabling earlier and more precise risk assessment without invasive procedures. The company is also leveraging AI to simulate blood flow non-invasively, further enhancing diagnostic capabilities. A major focus for Artrya is its Sapphire study, which aims to demonstrate how earlier detection—particularly in asymptomatic patients—could ...